Diseases & Conditions
Cheaper treatment for vision loss just as safe as expensive option
A review of the best available evidence by the Cochrane Collaboration found no clear difference in safety between two medications used to treat a common form of age-related vision loss. The Cochrane Collaboration consists of doctors, researchers, and patient advocates who conduct independent evaluations of the evidence for or against tests and treatments.
The review focused on bevacizumab (Avastin) and ranibizumab (Lucentis), the drugs used to treat age-related macular degeneration. The disease damages the light-sensitive retina in the back of the eye. Many doctors favor Lucentis, the more expensive option, because some research suggests it is safer.
To continue reading this article, you must log in.
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.
- Research health conditions
- Check your symptoms
- Prepare for a doctor's visit or test
- Find the best treatments and procedures for you
- Explore options for better nutrition and exercise
I'd like to receive access to Harvard Health Online for only $4.99 a month.
Sign Me UpAlready a member? Login ».
Disclaimer:
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.